Yuji Murakawa

JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.

Journal: Journal of arrhythmia

Published: December 16, 2022

JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: March 14, 2022

Systematic Screening for Atrial Fibrillation in Patients at Moderate-to-High Risk of Stroke　- Potential to Increase the Atrial Fibrillation Detection Rate (SCAN-AF).

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: February 07, 2022

Impact of three major risk factors on clinical outcomes in patients with nonvalvular atrial fibrillation receiving rivaroxaban: Sub-analysis from the XAPASS study.

Journal: Journal of arrhythmia

Published: October 18, 2021

CORRIGENDUM: JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: August 26, 2021

JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias.

Journal: Journal of arrhythmia

Published: August 13, 2021

JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: June 03, 2021

Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS.

Journal: PloS one

Published: December 08, 2020

Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation.

Journal: Heart and vessels

Published: November 18, 2019

Distinguishing coagulase-negative Staphylococcus bacteremia from contamination using blood-culture positive bottle detection pattern and time to positivity.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: August 29, 2019

Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.

Journal: Journal of thrombosis and thrombolysis

Published: August 22, 2019

Relationship of quantitative flow ratio after second-generation drug-eluting stent implantation to clinical outcomes.

Journal: Heart and vessels

Published: August 07, 2019

JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.

JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.

JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.

JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.

Systematic Screening for Atrial Fibrillation in Patients at Moderate-to-High Risk of Stroke - Potential to Increase the Atrial Fibrillation Detection Rate (SCAN-AF).

Systematic Screening for Atrial Fibrillation in Patients at Moderate-to-High Risk of Stroke - Potential to Increase the Atrial Fibrillation Detection Rate (SCAN-AF).

Impact of three major risk factors on clinical outcomes in patients with nonvalvular atrial fibrillation receiving rivaroxaban: Sub-analysis from the XAPASS study.

Impact of three major risk factors on clinical outcomes in patients with nonvalvular atrial fibrillation receiving rivaroxaban: Sub-analysis from the XAPASS study.

CORRIGENDUM: JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias.

CORRIGENDUM: JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias.

JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias.

JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias.

JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias.

JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias.

Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS.

Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS.

Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation.

Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation.

Distinguishing coagulase-negative Staphylococcus bacteremia from contamination using blood-culture positive bottle detection pattern and time to positivity.

Distinguishing coagulase-negative Staphylococcus bacteremia from contamination using blood-culture positive bottle detection pattern and time to positivity.

Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.

Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.

Relationship of quantitative flow ratio after second-generation drug-eluting stent implantation to clinical outcomes.

Relationship of quantitative flow ratio after second-generation drug-eluting stent implantation to clinical outcomes.

Systematic Screening for Atrial Fibrillation in Patients at Moderate-to-High Risk of Stroke　- Potential to Increase the Atrial Fibrillation Detection Rate (SCAN-AF).

Systematic Screening for Atrial Fibrillation in Patients at Moderate-to-High Risk of Stroke　- Potential to Increase the Atrial Fibrillation Detection Rate (SCAN-AF).